← back to search

Laura L. Hammitt

Johns Hopkins University · US
🔎 Find collaborators in Epidemiology · Microbiology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Epidemiology · Microbiology
Research interest
Research interests include Pneumonia and Respiratory Infections, Respiratory viral infections research, Bacterial Infections and Vaccines, and Influenza Virus Research Studies.
h-index
42
citations
15,550
works
170
NIH funding
primary concept
Medicine
email

Recent publications

Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project
Journal of Infection 2025cited by 10position: middledoi
Persistence of Vaccine Serotype Carriage and Differences in Pneumococcal Carriage by Laboratory Method and Sample Type in Indigenous Individuals in the Southwest United States.
2025cited by 2position: contributordoi
Impact of Pneumococcal Conjugate Vaccines on Otitis Media among American Indian/Alaska Native Children in the Southwest United States.
2025cited by 1position: contributordoi
Serotype-specific pneumococcal invasiveness: a global meta-analysis of paired estimates of disease incidence and carriage prevalence
2025cited by 1position: contributordoi
Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites.
2025cited by 0position: contributordoi
Clinical characterization of acute COVID-19 and Post-COVID-19 Conditions 3 months following infection: A cohort study among Indigenous adults and children in the Southwestern United States.
2025cited by 0position: contributordoi
Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis
The Lancet Infectious Diseases 2024cited by 67position: middledoi
Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis
The Lancet Infectious Diseases 2024cited by 55position: middledoi
Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
2024cited by 38position: contributordoi
Epidemiology of human metapneumovirus among children with severe or very severe pneumonia in high pneumonia burden settings: the Pneumonia Etiology Research for Child Health (PERCH) study experience
Clinical Microbiology and Infection 2024cited by 21position: middledoi
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
JCI Insight 2024cited by 12position: middledoi
Streptococcus pneumoniae serotype 3 population structure in the era of conjugate vaccines, 2001–2018
Microbial Genomics 2024cited by 3position: contributordoi
Trends in Otitis Media Ambulatory Visits in American Indian and Alaska Native Children During the Pneumococcal Conjugate Vaccine Period and the COVID-19 Pandemic.
2024cited by 2position: contributordoi
Factors predicting mortality in hospitalised HIV-negative children with lower-chest-wall indrawing pneumonia and implications for management
PLoS ONE 2024cited by 1position: middledoi
Linkage-based ortholog refinement in bacterial pangenomes with CLARC
2024cited by 0position: contributordoi
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants
New England Journal of Medicine 2023cited by 235position: middledoi
Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study
The Lancet Microbe 2023cited by 77position: middledoi
Early antibody treatment, inflammation, and risk of post-COVID conditions
mBio 2023cited by 21position: middledoi
Transfusion reactions associated with <scp>COVID</scp>‐19 convalescent plasma in outpatient clinical trials
Transfusion 2023cited by 11position: middledoi
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
Microbiology Spectrum 2023cited by 11position: middledoi
Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys
The Lancet Infectious Diseases 2023cited by 8position: middledoi
Effectiveness of COVID-19 mRNA Vaccines in Preventing COVID-19-Associated Outpatient Visits and Hospitalizations Among American Indian and Alaska Native Persons, January-November 2021: A Test-Negative Case-Control Analysis Using Surveillance Data.
2023cited by 7position: contributordoi
Prediction of post-PCV13 pneumococcal evolution using invasive disease data enhanced by inverse-invasiveness weighting
2023cited by 3position: contributordoi
<i>Streptococcus pneumoniae</i> serotype 3 population structure in the era of conjugate vaccines, 2001-2018
2023cited by 1position: contributordoi
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
2023cited by 0position: contributordoi
Early Outpatient Treatment for Covid-19 with Convalescent Plasma
New England Journal of Medicine 2022cited by 268position: middledoi
Digitally recorded and remotely classified lung auscultation compared with conventional stethoscope classifications among children aged 1–59 months enrolled in the Pneumonia Etiology Research for Child Health (PERCH) case–control study
BMJ Open Respiratory Research 2022cited by 11position: middledoi
Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project
Microorganisms 2021cited by 62position: middledoi
Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project
Microorganisms 2021cited by 59position: middledoi
Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
Microorganisms 2021cited by 23position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

J. Anthony G. Scott · Haramaya University21 papers (2012–2023) · 16 papers (2019–2025)Daniel R. Feikin · Centers for Disease Control and Prevention10 papers (2017–2021)Maria Deloria Knoll · University of the Witwatersrand10 papers (2017–2021)Katherine L. O’Brien · Twitter (United States)10 papers (2017–2021)David R. Murdoch · Christchurch Hospital10 papers (2012–2021) · 6 papers (2012–2023)Ifedayo Adetifa · Kenya Medical Research Institute6 papers (2016–2023) · 6 papers (2017–2021) · 6 papers (2014–2019)Angela Karani · University of London6 papers (2014–2023)Susan C. Morpeth · Middlemore Hospital6 papers (2014–2021)John Ojal · London School of Hygiene & Tropical Medicine5 papers (2014–2019)Shabir A. Madhi · Washington University in St. Louis5 papers (2017–2023)D. James Nokes · Kenya Medical Research Institute4 papers (2012–2021)David Goldblatt · Institute of Infection and Immunity4 papers (2014–2023) · 4 papers (2014–2019)Evasius Bauni · London School of Hygiene & Tropical Medicine4 papers (2016–2019)Tahreni Bwanaali · London School of Hygiene & Tropical Medicine4 papers (2014–2019)Donald M. Thea · Boston University4 papers (2017–2021)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Epidemiology · Microbiology →